Bucaloiu Ion D, Olenginski Thomas P, Harrington Thomas M
Department of Internal Medicine, Geisinger Medical Center, 100 N Academy Ave, Danville, PA 17822, USA.
Mayo Clin Proc. 2007 Dec;82(12):1510-5. doi: 10.1016/S0025-6196(11)61095-1.
To review the clinical and laboratory features of remitting seronegative symmetrical synovitis with pitting edema (RS3PE) in a rural tertiary care rheumatology practice, describe treatments and outcomes, and compare our results to previous reports in the literature.
We performed a retrospective chart review of all patients diagnosed as having RS3PE who were seen in the Department of Rheumatology at Geisinger Medical Center, Danville, PA, from January 1, 1992, to December 31, 2005.
We identified 12 men and 2 women, all of whom were white. Mean +/- SD age was 74.0 +/- 6.6 years; mean +/- SD erythrocyte sedimentation rate was 35.9 +/- 21.1 mm/h at presentation. Onset of illness was sudden in 9 patients and insidious in 5. All patients were initially treated with prednisone (15-20 mg/d). Although the response in all was excellent, 9 patients received disease-modifying antirheumatic drugs, either because of ongoing disease activity or in an effort to decrease the use of corticosteroids. Hydroxychloroquine was used alone in 7 patients. At the mean +/- SD time of last follow-up (31.4 +/- 23.1 months), 5 patients continued to receive therapy. Complications of treatment included worsening of preexisting hypertension in 3 patients, gastritis in 2, and exacerbation of preexisting diabetes mellitus in 1. Carpal tunnel syndrome occurred in 6 patients. Duration of therapy ranged from 5 to 120 months (mean, 29 months). Three patients developed malignancies, ie, non-Hodgkin lymphoma, transitional cell carcinoma of the bladder, and prostate carcinoma.
Our population of patients with RS3PE is similar to those documented in previous reports: elderly, predominantly male, and responsive to corticosteroids. However, our series is clinically differentiated by a greater use of adjunctive disease-modifying antirheumatic drugs (primarily hydroxychloroquine). Confirming previous reports, we also observed a possible association between RS3PE and malignancy.
回顾在农村三级医疗风湿病诊疗机构中缓解性血清阴性对称性滑膜炎伴凹陷性水肿(RS3PE)的临床和实验室特征,描述治疗方法及结果,并将我们的结果与文献中先前的报道进行比较。
我们对1992年1月1日至2005年12月31日期间在宾夕法尼亚州丹维尔市盖辛格医疗中心风湿病科就诊且被诊断为RS3PE的所有患者进行了回顾性病历审查。
我们确定了12名男性和2名女性,均为白人。平均年龄±标准差为74.0±6.6岁;就诊时平均红细胞沉降率±标准差为35.9±21.1mm/h。9例患者起病突然,5例起病隐匿。所有患者最初均接受泼尼松治疗(15 - 20mg/d)。尽管所有患者的反应都很好,但9例患者因疾病持续活动或为减少皮质类固醇的使用而接受了改善病情抗风湿药物治疗。7例患者单独使用了羟氯喹。在平均±标准差的末次随访时间(31.4±23.1个月)时,5例患者继续接受治疗。治疗并发症包括3例患者原有高血压病情加重、2例胃炎、1例原有糖尿病病情加重。6例患者发生腕管综合征。治疗持续时间为5至120个月(平均29个月)。3例患者发生恶性肿瘤,即非霍奇金淋巴瘤、膀胱移行细胞癌和前列腺癌。
我们的RS3PE患者群体与先前报道的相似:以老年人为主,男性居多,对皮质类固醇有反应。然而,我们的系列病例在临床上的特点是更多地使用辅助性改善病情抗风湿药物(主要是羟氯喹)。与先前报道一致,我们还观察到RS3PE与恶性肿瘤之间可能存在关联。